RJA
ELDN icon

Raymond James & Associates’s Eledon Pharmaceuticals ELDN Stock Holding History

Raymond James & Associates’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-611
Closed -$10K – 3800
2020
Q3 		$10K Buy
+611
New +$6.02K ﹤0.01% 3542
2019
Q2 		– Sell
-608
Closed -$44K – 3674
2019
Q1 		$44K Hold
608
– – ﹤0.01% 3483
2018
Q4 		$18K Hold
608
– – ﹤0.01% 3440
2018
Q3 		$51K Buy
+608
New +$62.1K ﹤0.01% 3491

Other funds holding ELDN

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Raymond James & Associates's ELDN Position: Q4 2020 in Review

Raymond James & Associates sold out of Eledon Pharmaceuticals (ELDN) in Q4 2020, closing a stake of 611 shares — an estimated $10K sold.

Raymond James & Associates first reported a position in ELDN in Q3 2018 and held it in 4 quarters. The position peaked at $51K in Q3 2018. 21 funds tracked by Wall St. Rank hold ELDN as of Q4 2020.

  • Raymond James & Associates reported no remaining Eledon Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 611 Eledon Pharmaceuticals shares in Q4 2020, an estimated $10K.
  • Raymond James & Associates first reported a position in Eledon Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Raymond James & Associates's Eledon Pharmaceuticals position peaked at $51K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.